SG Americas Securities LLC Trims Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

SG Americas Securities LLC lowered its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 61.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,506 shares of the medical device company’s stock after selling 5,483 shares during the period. SG Americas Securities LLC’s holdings in Tandem Diabetes Care were worth $126,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of TNDM. Brooklyn Investment Group bought a new position in Tandem Diabetes Care in the 3rd quarter worth approximately $28,000. Assetmark Inc. bought a new position in shares of Tandem Diabetes Care during the third quarter worth $29,000. ORG Wealth Partners LLC purchased a new position in Tandem Diabetes Care during the third quarter valued at $30,000. Waldron Private Wealth LLC bought a new stake in Tandem Diabetes Care in the 3rd quarter valued at $50,000. Finally, McIlrath & Eck LLC purchased a new stake in Tandem Diabetes Care in the 3rd quarter worth $52,000.

Insider Buying and Selling

In related news, Director Kim D. Blickenstaff sold 10,000 shares of the company’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the transaction, the director now directly owns 195,190 shares of the company’s stock, valued at $5,855,700. This represents a 4.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 2.20% of the stock is currently owned by company insiders.

Tandem Diabetes Care Price Performance

Shares of TNDM stock opened at $33.52 on Wednesday. Tandem Diabetes Care, Inc. has a twelve month low of $22.03 and a twelve month high of $53.69. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -17.37 and a beta of 1.32. The stock has a fifty day simple moving average of $35.48 and a two-hundred day simple moving average of $37.09. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29.

Analyst Ratings Changes

A number of equities research analysts recently commented on TNDM shares. Sanford C. Bernstein initiated coverage on Tandem Diabetes Care in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 target price on the stock. Robert W. Baird reduced their price objective on Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a research note on Thursday, November 7th. Canaccord Genuity Group reduced their price objective on Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Barclays lifted their price objective on Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. Finally, Citigroup cut their target price on Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Tandem Diabetes Care presently has an average rating of “Moderate Buy” and a consensus target price of $53.81.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.